Regulatory

Dec 12, 2016
Pharmaceutical Executive
Republican control of Washington promises overhaul of healthcare and medical product regulation.
Dec 08, 2016
Uncertainty surrounds the future of drug pricing reform, causing industry observers to take a closer look at the policy views of the president-elect, state and Congressional lawmakers, and the general public.
Dec 05, 2016
Congress took a major step last month towards shoring up FDA operations and biomedical research supported by the National Institutes of Health with House passage of the 21st Century Cures bill.
Nov 29, 2016
The European Medicine Association is determined keep open all options on the future of drug approvals in advance of a crucial meeting in December, writes Reflector.
Nov 29, 2016
Biosimilars are gaining more support among payers and physicians, but more needs to be done to explain their benefits as well as their safety and efficacy profiles, writes Barbara Testa.
Nov 18, 2016
Biopharma companies should no longer consider FDA an obstacle to innovation and in need of major reform, according to Jim Greenwood, President of BIO.
Nov 09, 2016
The surprise victory of Donald Trump opens the door to new strategies for providing healthcare to Americans, including coverage and oversight of prescription drugs.
Nov 02, 2016
Policymakers, payers and pharma companies weigh strategies for rationalizing drug prices
. Jill Wechsler reports.
Nov 02, 2016
FDA officials agree that large comparative clinical trials defeat the purpose of the abbreviated development program for biosimilars.
Oct 27, 2016
The FDA approved Sarepta’s Exondys for Duchenne muscular dystrophy despite little evidence of efficacy.
native1_300x100
lorem ipsum